Biofrontera Inc.
About Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $41.7M
- Net income
- -$10.5M
- Total assets
- $28.6M
- Market cap
- $12.0M
- Operating margin
- -27.2%
- Net margin
- -25.3%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $41.7M
- Operating expenses
- $53.1M
- Operating income
- -$11.3M
- Income tax
- $25.0K
- Net income
- -$10.5M
- EPS (basic)
- $-1.04
- EPS (diluted)
- $-1.04
Balance sheet
- Total assets
- $28.6M
- Current assets
- $18.1M
- Total liabilities
- $18.1M
- Current liabilities
- $11.9M
- Shareholders’ equity
- $10.5M
Cash flow
- Operating cash flow
- -$13.4M
- Investing cash flow
- $3.0M
- Financing cash flow
- $10.8M
- Net cash flow
- $487.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $12.0M
- EPS (diluted)
- $-1.04
- Shares outstanding
- 12.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 29, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $10.5M in FY2025.
- Revenue grew 73% from FY2021 to FY2025.
- Trading 20% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Biofrontera Inc..
Write a review
News about Biofrontera Inc.
News & sentiment via Polygon.io
